NCT06565611 - A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity | Biotech Hunter

Enrollment

108

Participants

Timeline

Start Date

August 5, 2024

Primary Completion Date

February 5, 2025

Study Completion Date

March 31, 2025

Conditions

Obesity

Interventions

DRUG

bremelanotide

bremelanotide (BMT) sterile aqueous solution for subcutaneous injection, provided as autoinjectors containing 0.3 mL volume

DRUG

tirzepatide

tirzepatide (GLP-1/GIP) will be provided in its commercial form for SC injection.

Trial Locations (4)

University Clinical Research-DeLand LLC, d/b/a Accel Research, DeLand

Lynn Institute of Chattanooga, Chattanooga

Lynn Health Science Institute, Oklahoma City

Coastal Carolina Research Center, North Charleston